The von Hippel-Lindau tumor suppressor protein: New insights into oxygen sensing and cancer

Current Opinion in Genetics and Development

Volumn 13, Issue 1, 2003, Pages 55-60

  Kim, William ^a   Kaelin Jr , William G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; LIGASE; OXYGEN; PROLINE DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ALPHA CHAIN; CANCER; GENE TARGETING; HEMANGIOBLASTOMA; HUMAN; HYDROXYLATION; KIDNEY CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; REMOTE SENSING; REVIEW; SIGNAL TRANSDUCTION; VON HIPPEL LINDAU DISEASE;

EID: 0037307858     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(02)00010-2     Document Type: Review

References (60)

1. Kaelin W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer. 2:2002;673-682.
2. Hoffman M., Ohh M., Yang H., Klco J., Ivan M., Kaelin W.G. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10:2001;1019-1027.
3. Clifford S., Cockman M., Smallwood A., Mole D., Woodward E., Maxwell P., Ratcliffe P., Maher E. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 10:2001;1029-1038.
4. Hansen W., Ohh M., Moslehi J., Kondo K., Kaelin W., Welch W. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol. Cell. Biol. 22:2002;1947-1960.
5. Feldman D., Thulasiraman V., Ferreyra R., Frydman J. Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. Mol. Cell. 4:1999;1051-1061.
6. Schoenfeld A.R., Davidowitz E.J., Burk R.D. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc. Natl. Acad. Sci. USA. 97:2000;8507-8512.
7. Kamura T., Brower C.S., Conaway R.C., Conaway J.W. A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase. J. Biol. Chem. 277:2002;30388-30393.
8. Ohh M., Kim W.Y., Moslehi J.J., Chen Y., Chau V., Read M.A., Kaelin W.G. Jr. An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep. 3:2002;177-182.
9. Wada H., Yeh E., Kwamitani T. Identification of NEDD8-conjugation site in human cullin-2. Biochem. Biophys. Res. Commun. 257:1999;100-105.
10. Liakopoulos D., Busgen T., Brychzy A., Jentsch S., Pause A. Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function. Proc. Natl. Acad. Sci. USA. 96:1999;5510-5515.
11. Hori T., Osaka F., Chiba T., Miyamoto C., Okabayashi K., Shimbara N., Kato S., Tanaka K. Covalent modification of all members of human cullin family proteins by NEDD8. Oncogene. 18:1999;6829-6834.
12. Kawakami T., Chiba T., Suzuki T., Iwai K., Yamanaka K., Minato N., Suzuki H., Shimbara N., Hidaka Y., Osaka F.et al. NEDD8 recruits E2-ubiquitin to SCF E3 ligase. EMBO J. 20:2001;4003-4012.
13. Groulx I., Lee S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 22:2002;5319-5336.
14. 2-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. EMBO Rep. 2:2001;615-620.
15. •].
16. •].
17. •], show that binding of pVHL to HIF is regulated by enzymatic hydroxylation of a conserved prolyl residue within the HIF oxygen-dependent degradation domain. As oxygen is required for hydroxylation, these papers provide a satisfying explanation for why HIF turnover is oxygen-dependent. Moreover, these studies provided the first evidence for a role of protein hydroxylation in intracellular signaling.
18. Yu F., White S., Zhao Q., Lee F. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. Cancer Res. 61:2001;4136-4142.
19. Masson N., Willam C., Maxwell P., Pugh C., Ratcliffe P. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroylation. EMBO. 20:2001;5197-5206.
20. Kaelin W.G. Jr. How oxygen makes its presence felt. Genes Dev. 16:2002;1441-1445.
21. •].
22. •], reveal why binding of pVHL to HIF depends upon prolyl hydroxylation. The prolyl hydroxy group forms critical hydrogen bonds with two hydrophilic pVHL side-chains located in the otherwise hydrophobic pVHL β domain. In the unbound state these two side chains are partially solvent-exposed. Binding to HIF leads to the removal of the solvent groups, which would destabilize the pVHL structure were it not for these two hydrogen bonds, which cannot form with unmodified proline.
23. Schofield C.J., Zhang Z. Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr. Opin. Struct. Biol. 9:1999;722-731.
24. Kivirikko K.I., Myllyharju J. Prolyl 4-Hydroxylases and their protein disulfide isomerase subunit. Matrix Biol. 16:1998;357-368.
25. Aravind L, Koonin EV: The DNA-repair protein AlkB, EGL-9, and leprecan define new families of 2-oxoglutarate- and iron-dependent dioxygenases. Genome Biol 2001, 2:reasearch0007.0001-0007.0008.
26. Taylor M.S. Characterization and comparative analysis of the EGLN gene family. Gene. 275:2001;125-132.
27. •].
28. •] showed that Egl9 is the HIF prolyl hydroxylase using bioinformatic and genetic approaches, followed by biochemical validation experiments.
29. Ivan M., Haberberger T., Gervasi D., Michelson K., Gunzler V., Kondo K., Yang H., Sorokina I., Conaway R., Conaway J.et al. Biochemical purification and pharmacological inhibition of a mammalian HIF prolyl hydroxylase. Proc. Natl. Acad. Sci. USA. 99:2002;13459-13464 The authors of this paper identify a series of structurally diverse small-molecule EGLN antagonists. One such compound, FG-0041, activated HIF and HIF target genes in cell-based assays and was shown earlier [60] to be protective in a rat model of myocardial ischemia.
30. Sang N., Fang J., Srinivas V., Leshchinsky I., Caro J. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol. Cell. Biol. 22:2002;2984-2992.
31. Lando D., Peet D., Whelan D., Gorman J., Whitelaw M. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 295:2002;858-861 This paper is the first to demonstrate that the transcriptional-activation function of the HIF CTAD is regulated by oxygen-dependent hydroxylation of a conserved asparagine residue.
32. •].
33. •] show that FIH-1, the HIF-interacting protein identified earlier by Mahon et al. [36], is the enzyme responsible for the asparaginyl hydroxylation of HIF.
34. Freedman S., Sun Z., Poy F., Kung A., Livingston D., Wagner G., Eck M. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1alpha. Proc. Natl. Acad. Sci. USA. 99:2002;5367-5372.
35. Dames S., Martinez-Yamout M., De Guzman R., Dyson H., Wright P. From the cover: structural basis for Hif-1alpha /CBP recognition in the cellular hypoxic response. Proc. Natl. Acad. Sci. USA. 99:2002;5271-5276.
36. Mahon P., Hirota K., Semenza G. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15:2001;2675-2686.
37. Willam C., Masson N., Tian Y.M., Mahmood S.A., Wilson M.I., Bicknell R., Eckardt K.U., Maxwell P.H., Ratcliffe P.J., Pugh C.W. Peptide blockade of HIFalpha degradation modulates cellular metabolism and angiogenesis. Proc. Natl. Acad. Sci. USA. 99:2002;10423-10428.
38. Gothie E., Richard D., Berra E., Pages G., Pouyssegur J. Identification of alternative spliced variants of human hypoxia-inducible factor-1alpha. J. Biol. Chem. 275:2000;6922-6927.
39. Bindra R.S., Vasselli J.R., Stearman R., Linehan W.M., Klausner R.D. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 62:2002;3014-3019.
40. Zatyka M., da Silva N.F., Clifford S.C., Morris M.R., Wiesener M.S., Eckardt K.U., Houlston R.S., Richards F.M., Latif F., Maher E.R. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res. 62:2002;3803-3811.
41. Davidowitz E., Schoenfeld A., Burk R. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol. Cell Biol. 21:2001;865-874.
42. Okuda H., Saitoh K., Hirai S., Iwai K., Takaki Y., Baba M., Minato N., Ohno S., Shuin T. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J. Biol. Chem. 276:2001;43611-43617.
43. Okuda H., Hirai S., Takaki Y., Kamada M., Baba M., Sakai N., Kishida T., Kaneko S., Yao M., Ohno S.et al. Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem. Biophys. Res. Commun. 263:1999;491-497.
44. Zhou M.I., Wang H., Ross J.J., Kuzmin I., Xu C., Cohen H.T. The von Hippel-Lindau (VHL) tumor suppressor stabilizes novel PHD protein Jade-1. J. Biol. Chem. 277:2002;39887-39898.
45. Li Z., Wang D., Na X., Schoen S.R., Messing E.M., Wu G. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochem. Biophys. Res. Commun. 294:2002;700-709.
46. Li Z., Na X., Wang D., Schoen S.R., Messing E.M., Wu G. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 277:2002;4656-4662.
47. Datta K., Sundberg C., Karumanchi S.A., Mukhopadhyay D. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res. 61:2001;1768-1775.
48. Datta K., Nambudripad R., Pal S., Zhou M., Cohen H.T., Mukhopadhyay D. Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J. Biol. Chem. 275:2000;20700-20706.
49. Pal S., Claffey K., Dvorak H., Mukhopadhyay D. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J. Biol. Chem. 272:1997;27509-27512.
50. Pal S., Claffey K., Cohen H., Mukhopadhyay D. Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C ζ J. Biol. Chem. 273:1998;26277-26280.
51. de Paulsen N., Brychzy A., Fournier M.-C., Klausner R.D., Gnarra J.R., Pause A., Lee S. Role of transforming growth factor-alpha in VHL-/- clear cell renal carcinoma cell proliferation: a possible mechanism coupling von Hippel-Lindau tumor suppressor inactivation and tumorigenesis. Proc. Natl. Acad. Sci. USA. 13:2001;1387-1392.
52. •].
53. •] shows that a HIF2α variant bearing a proline-to-alanine mutation could promote renal carcinoma cell growth in vivo despite the presence of wild-type pVHL.
54. Aiello L., George D., Cahill M., Wong J., Cavallerano J., Hannah A., Kaelin W.G. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome and optic nerve head hemangioma following systemic treatment with the VEGF receptor inhibitor SU5416. Ophthalmology. 109:2002;1745-1751.
55. Richard S., Croisille L., Yvart J., Casadeval N., Eschwege P., Aghakhani N., David P., Gaudric A., Scigalla P., Hermine O. Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood. 99:2002;3851-3853.
56. Yang J., Haworth S., Steinberg S., Rosenberg S., Novotny W. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;15.
57. Fabbro D., Parkinson D., Matter A. Protein tyrosine kinase inhibitors: new treatment modalities? Curr. Opin. Pharmacol. 2:2002;374-381.
58. Vincent K., Shyu K., Luo Y., Magner M., Tio R., Jiang C., Goldberg M., Akita G., Gregory R., Isner J. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation. 102:2000;2255-2261.
59. Elson D, Thurston G, Huang L, Ginzinger D, McDonald D, Johnson R, Arbeit J: Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α. Genes Dev 2001, 15:2520-2532.
60. Nwogu J.I., Geenen D., Bean M., Brenner M.B., Huang X., Buttrick P.M. Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilation after myocardial infarction. Circulation. 104:2001;2216-2221.